Abstract
Malignant mesothelioma is an aggressive disease with dismal prognosis despite multimodal treatment including chemotherapy, surgery and radiotherapy. At progression it is possible to provide systemic second-line treatment but its effects are limited. Herein we report two patient cases with mesothelioma who received second-line chemotherapy with the combination of cisplatin and the novel compound lurbinectedin. The combination showed promising activity in both cases with manageable toxicity. We discuss the results of this regime in the light of historical as well as emerging data in mesothelioma.
Keywords:
Lurbinectedin; Mesothelioma; Palliative chemotherapy.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Carbolines / administration & dosage
-
Carbolines / adverse effects
-
Cisplatin / administration & dosage
-
Cisplatin / adverse effects
-
Clinical Trials, Phase I as Topic
-
Combined Modality Therapy
-
Heterocyclic Compounds, 4 or More Rings / administration & dosage
-
Heterocyclic Compounds, 4 or More Rings / adverse effects
-
Humans
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / radiotherapy
-
Lung Neoplasms / surgery
-
Male
-
Mesothelioma / drug therapy*
-
Mesothelioma / radiotherapy
-
Mesothelioma / surgery
-
Mesothelioma, Malignant
-
Palliative Care / methods*
-
Pleural Neoplasms / drug therapy*
-
Pleural Neoplasms / radiotherapy
-
Pleural Neoplasms / surgery
-
Prognosis
Substances
-
Carbolines
-
Heterocyclic Compounds, 4 or More Rings
-
PM 01183
-
Cisplatin